These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 27003901)

  • 1. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study.
    Takayama K; Atagi S; Imamura F; Tanaka H; Minato K; Harada T; Katakami N; Yokoyama T; Yoshimori K; Takiguchi Y; Hataji O; Takeda Y; Aoe K; Kim YH; Yokota S; Tabeta H; Tomii K; Ohashi Y; Eguchi K; Watanabe K
    Support Care Cancer; 2016 Aug; 24(8):3473-80. PubMed ID: 27003901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.
    Takayama K; Katakami N; Yokoyama T; Atagi S; Yoshimori K; Kagamu H; Saito H; Takiguchi Y; Aoe K; Koyama A; Komura N; Eguchi K
    Support Care Cancer; 2016 Aug; 24(8):3495-505. PubMed ID: 27005463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced non-small cell lung cancer.
    Mohan A; Singh P; Kumar S; Mohan C; Pathak AK; Pandey RM; Guleria R
    Asian Pac J Cancer Prev; 2008; 9(4):557-62. PubMed ID: 19256738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia.
    Salsman JM; Beaumont JL; Wortman K; Yan Y; Friend J; Cella D
    Support Care Cancer; 2015 May; 23(5):1355-64. PubMed ID: 25351456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer.
    LeBlanc TW; Nipp RD; Rushing CN; Samsa GP; Locke SC; Kamal AH; Cella DF; Abernethy AP
    J Pain Symptom Manage; 2015 Apr; 49(4):680-9. PubMed ID: 25461669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.
    Nishie K; Yamamoto S; Nagata C; Koizumi T; Hanaoka M
    Lung Cancer; 2017 Oct; 112():25-34. PubMed ID: 29191597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS).
    LeBlanc TW; Samsa GP; Wolf SP; Locke SC; Cella DF; Abernethy AP
    Support Care Cancer; 2015 Aug; 23(8):2341-7. PubMed ID: 25586527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.
    Srdic D; Plestina S; Sverko-Peternac A; Nikolac N; Simundic AM; Samarzija M
    Support Care Cancer; 2016 Nov; 24(11):4495-502. PubMed ID: 27236439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.
    Currow D; Temel JS; Abernethy A; Milanowski J; Friend J; Fearon KC
    Ann Oncol; 2017 Aug; 28(8):1949-1956. PubMed ID: 28472437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer.
    Agteresch HJ; Dagnelie PC; van der Gaast A; Stijnen T; Wilson JH
    J Natl Cancer Inst; 2000 Feb; 92(4):321-8. PubMed ID: 10675381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
    Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
    Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.
    Miura K; Shukuya T; Furuya N; Morita R; Kisohara A; Mouri A; Watanabe S; Tanaka H; Hirata A; Hakozaki T; Hamai K; Matsumoto N; Watanabe K; Ashinuma H; Miyauchi E; Sugano K; Hosokawa S; Amano K; Morita S; Kobayashi K; Maemonodo M; Takahashi K
    J Cachexia Sarcopenia Muscle; 2024 Dec; 15(6):2618-2628. PubMed ID: 39351653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study.
    Sánchez-Lara K; Turcott JG; Juárez E; Guevara P; Núñez-Valencia C; Oñate-Ocaña LF; Flores D; Arrieta O
    Nutr Cancer; 2012; 64(4):526-34. PubMed ID: 22489794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks.
    van der Meij BS; Schoonbeek CP; Smit EF; Muscaritoli M; van Leeuwen PA; Langius JA
    Br J Nutr; 2013 Jun; 109(12):2231-9. PubMed ID: 23153477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Socioeconomic Status on Pretreatment Weight Loss and Survival in Non-Small-Cell Lung Cancer.
    Lau SKM; Gannavarapu BS; Carter K; Gao A; Ahn C; Meyer JJ; Sher DJ; Jatoi A; Infante R; Iyengar P
    J Oncol Pract; 2018 Apr; 14(4):e211-e220. PubMed ID: 29558251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality burden of pre-treatment weight loss in patients with non-small-cell lung cancer: A systematic literature review and meta-analysis.
    Bonomi PD; Crawford J; Dunne RF; Roeland EJ; Smoyer KE; Siddiqui MK; McRae TD; Rossulek MI; Revkin JH; Tarasenko LC
    J Cachexia Sarcopenia Muscle; 2024 Aug; 15(4):1226-1239. PubMed ID: 38650388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) in lung cancer patients with involuntary weight loss.
    Gelhorn HL; Gries KS; Speck RM; Duus EM; Bourne RK; Aggarwal D; Cella D
    Qual Life Res; 2019 Jun; 28(6):1641-1653. PubMed ID: 30796591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a patient-centered aggregate score to predict survival after lung resection for non-small cell lung cancer.
    Brunelli A; Salati M; Refai M; Xiumé F; Berardi R; Mazzanti P; Pompili C
    J Thorac Cardiovasc Surg; 2013 Aug; 146(2):385-90.e1-2. PubMed ID: 23651911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-diagnosis weight loss as a prognostic factor in non-small cell lung cancer.
    Mytelka DS; Li L; Benoit K
    J Cachexia Sarcopenia Muscle; 2018 Feb; 9(1):86-92. PubMed ID: 29205930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer.
    Yi YS; Ban WH; Sohng KY
    BMC Cancer; 2018 Oct; 18(1):1053. PubMed ID: 30373585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.